Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

VK2735 is being developed in oral and subcutaneous formulations for metabolic disorders such as obesity.

The Phase 2 VENTURE-Oral Dosing trial achieved its primary and secondary endpoints, with patients receiving VK2735 demonstrating statistically significant reductions in body weight compared with placebo.

Additionally, the study demonstrated that VK2735 treatment was safe and well-tolerated over 13 weeks of daily dosing, with most treatment-emergent adverse events (TEAEs) categorized as mild or moderate.

Also Read: Eli Lilly’s Rare Weight Loss Data Miss Could Benefit Competitors

Participants receiving once-daily doses of the oral VK2735 demonstrated up to a 12.2% reduction in mean body weight after 13 weeks from baseline.

Participants receiving VK2735 showed up to a 10.9% reduction in body weight compared ...